JP2013541334A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541334A5
JP2013541334A5 JP2013529298A JP2013529298A JP2013541334A5 JP 2013541334 A5 JP2013541334 A5 JP 2013541334A5 JP 2013529298 A JP2013529298 A JP 2013529298A JP 2013529298 A JP2013529298 A JP 2013529298A JP 2013541334 A5 JP2013541334 A5 JP 2013541334A5
Authority
JP
Japan
Prior art keywords
independently
occurrence
duplex agent
irna duplex
irna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013529298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051597 external-priority patent/WO2012037254A1/en
Publication of JP2013541334A publication Critical patent/JP2013541334A/ja
Publication of JP2013541334A5 publication Critical patent/JP2013541334A5/ja
Pending legal-status Critical Current

Links

JP2013529298A 2010-09-15 2011-09-14 修飾されたiRNA剤 Pending JP2013541334A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38325010P 2010-09-15 2010-09-15
US61/383,250 2010-09-15
PCT/US2011/051597 WO2012037254A1 (en) 2010-09-15 2011-09-14 MODIFIED iRNA AGENTS

Publications (2)

Publication Number Publication Date
JP2013541334A JP2013541334A (ja) 2013-11-14
JP2013541334A5 true JP2013541334A5 (enExample) 2014-10-30

Family

ID=44764215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529298A Pending JP2013541334A (ja) 2010-09-15 2011-09-14 修飾されたiRNA剤

Country Status (6)

Country Link
US (1) US9290760B2 (enExample)
EP (1) EP2616543A1 (enExample)
JP (1) JP2013541334A (enExample)
AU (1) AU2011302152B2 (enExample)
CA (1) CA2812046A1 (enExample)
WO (1) WO2012037254A1 (enExample)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513843T1 (de) * 2002-09-25 2011-07-15 Univ Massachusetts Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
CN104212799B (zh) 2008-10-15 2018-11-23 Ionis制药公司 因子11表达的调节
HRP20150796T1 (hr) 2008-10-20 2015-09-11 Alnylam Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju ekspresije transtiretina
CA2818662C (en) 2010-10-22 2021-07-06 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecule inducing rna interference, and uses thereof
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
CN106434665B (zh) 2011-06-30 2021-06-08 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
EP2751270B1 (en) 2011-08-29 2018-08-22 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
MY167390A (en) 2011-11-18 2018-08-16 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
KR20250133484A (ko) * 2011-11-18 2025-09-05 알닐람 파마슈티칼스 인코포레이티드 변형된 RNAi 제제
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
EP3514236A1 (en) * 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス, インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
DK2879718T3 (da) * 2012-08-06 2023-06-19 Alnylam Pharmaceuticals Inc Proces til fremstilling af kulhydratkonjugerede RNA-stoffer
US9879041B2 (en) 2012-11-28 2018-01-30 Victoria Link Limited Saccharide dendritic cluster compounds as inhibitors of BACE-1
TW201446791A (zh) * 2013-05-01 2014-12-16 Regulus Therapeutics Inc 用於調節mir-122之微小rna化合物及方法
KR102482890B1 (ko) * 2013-05-01 2022-12-30 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
AU2014284152B2 (en) 2013-06-21 2020-01-23 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015085158A1 (en) 2013-12-06 2015-06-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
KR102344559B1 (ko) 2013-12-12 2021-12-31 알닐람 파마슈티칼스 인코포레이티드 보체 성분 iRNA 조성물 및 이의 이용 방법
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
WO2015143246A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
CN106232125B (zh) 2014-05-01 2020-10-16 Ionis制药公司 用于调节pkk表达的组合物和方法
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
CN110903337A (zh) * 2014-05-01 2020-03-24 Ionis制药公司 用于调节生长激素受体表达的组合物和方法
PE20170010A1 (es) 2014-05-01 2017-03-04 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del factor b del complemento
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN107532162A (zh) 2014-12-12 2018-01-02 托德·M·伍尔夫 用于利用寡核苷酸编辑细胞中核酸的组合物和方法
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
JP6667179B2 (ja) 2015-03-24 2020-03-18 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
US20180193471A1 (en) * 2015-07-16 2018-07-12 Kyowa Hakko Kirin Co., Ltd. ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE
ES2842300T3 (es) 2015-07-31 2021-07-13 Alnylam Pharmaceuticals Inc Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스 감염에 대한 rnai 치료법
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
TW201723176A (zh) 2015-09-24 2017-07-01 Ionis製藥公司 Kras表現之調節劑
US10533175B2 (en) 2015-09-25 2020-01-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Ataxin 3 expression
CA2998898A1 (en) 2015-10-08 2017-04-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
DK4119569T3 (da) 2015-11-06 2024-08-12 Ionis Pharmaceuticals Inc Konjugerede antisense-forbindelser til anvendelse i behandling
CA2999341A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
EP3397288A4 (en) 2015-12-31 2019-09-11 Ionis Pharmaceuticals, Inc. PROCESS FOR REDUCING ATAXIN-2 EXPRESSION
EP3400300A4 (en) 2016-01-05 2019-08-07 Ionis Pharmaceuticals, Inc. PROCESS FOR REDUCING LRRK2 EXPRESSION
WO2017134526A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
CN108779463B (zh) 2016-02-02 2022-05-24 奥利克斯医药有限公司 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘
CN109069529B (zh) 2016-03-07 2021-08-20 箭头药业股份有限公司 用于治疗性化合物的靶向配体
US10577607B2 (en) 2016-03-16 2020-03-03 Ionis Pharmaceuticals, Inc. Modulation of DYRK1B expression
EP3429690A4 (en) 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. METHOD FOR MODULATING KEAP1
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
CA3022319A1 (en) 2016-05-06 2017-11-09 Tod M. Woolf Improved methods for genome editing with and without programmable nucleases
EP3469073B1 (en) 2016-06-09 2024-01-10 Centre National de la Recherche Scientifique (CNRS) Raav with chemically modified capsid
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3484524B1 (en) 2016-07-15 2022-11-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of smn2
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
CN109462981B (zh) 2016-09-02 2023-07-07 箭头药业股份有限公司 靶向配体
CN109661233A (zh) 2016-10-06 2019-04-19 Ionis 制药公司 缀合低聚化合物的方法
US10131911B2 (en) 2016-11-07 2018-11-20 nanoSUR LLC Post-transcriptionally chemically modified double strand RNAs
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
WO2018102745A1 (en) 2016-12-02 2018-06-07 Cold Spring Harbor Laboratory Modulation of lnc05 expression
US11591600B2 (en) 2017-02-10 2023-02-28 OliX Pharmaceuticals. Inc. Long double-stranded RNA for RNA interference
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
EP3603648B1 (en) 2017-03-29 2025-09-17 Shionogi & Co., Ltd Complex of nucleic acid medicine and multibranched lipid
LT3607069T (lt) 2017-04-05 2023-01-10 Silence Therapeutics Gmbh Produktai ir kompozicijos
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018223081A1 (en) * 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11197884B2 (en) 2017-08-18 2021-12-14 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
MA50267A (fr) 2017-09-19 2020-07-29 Alnylam Pharmaceuticals Inc Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
KR102834361B1 (ko) 2017-12-01 2025-07-17 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
JP7348185B2 (ja) 2017-12-21 2023-09-20 アルニラム ファーマスーティカルズ インコーポレイテッド キラル富化二本鎖rna剤
CA3087106A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
AU2019206731A1 (en) 2018-01-15 2020-07-30 Ionis Pharmaceuticals, Inc. Modulators of DNM2 expression
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
TWI840345B (zh) 2018-03-02 2024-05-01 美商Ionis製藥公司 Irf4表現之調節劑
EP3759127A4 (en) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
CN115976028B (zh) 2018-03-09 2025-03-25 第一三共株式会社 糖原病Ia型治疗药
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
US11365416B2 (en) 2018-04-11 2022-06-21 Ionis Pharmaceuticals, Inc. Modulators of EZH2 expression
SG11202010910QA (en) 2018-05-07 2020-12-30 Alnylam Pharmaceuticals Inc Extrahepatic delivery
CN112400020B (zh) 2018-05-08 2024-11-19 莱古路斯治疗法股份有限公司 作为具有hcv抗病毒活性与降低的高胆红素血症副作用的mir-122抑制剂的galnac缀合的经修饰的寡核苷酸
WO2019217708A1 (en) 2018-05-09 2019-11-14 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
US20210355497A1 (en) 2018-05-09 2021-11-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fxi expression
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2019241648A1 (en) 2018-06-14 2019-12-19 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing stmn2 expression
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
MX2021000922A (es) 2018-07-25 2021-03-31 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de la atxn2.
EP3833397A4 (en) 2018-08-08 2023-06-14 Arcturus Therapeutics, Inc. COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
EP3833763A4 (en) 2018-08-10 2023-07-19 University of Massachusetts MODIFIED OLIGONUCLEOTIDES FOR TARGETING SNPS
JP2021533800A (ja) 2018-08-21 2021-12-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
TWI869213B (zh) 2018-09-19 2025-01-01 美商Ionis製藥公司 Pnpla3表現之調節劑
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
WO2020102630A1 (en) 2018-11-15 2020-05-22 Ionis Pharmaceuticals, Inc. Modulators of irf5 expression
MY205095A (en) 2018-11-21 2024-10-01 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
UA128236C2 (uk) 2018-12-21 2024-05-15 Айоніс Фармасутікалз, Інк. Модулятори експресії hsd17b13
JP2022523467A (ja) * 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ 動的な薬物動態を修飾するアンカー
US11214803B2 (en) 2019-01-31 2022-01-04 Ionis Pharmaceuticals, Inc. Modulators of YAP1 expression
KR20210134686A (ko) 2019-02-27 2021-11-10 아이오니스 파마수티컬즈, 인코포레이티드 Malat1 발현의 조절인자
CN117431244A (zh) 2019-03-29 2024-01-23 Ionis制药公司 用于调节ube3a-ats的化合物和方法
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4660307A2 (en) 2019-07-26 2025-12-10 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
CA3150715A1 (en) 2019-09-10 2021-03-18 Makoto Koizumi Conjugate of galnac-oligonucleotide for delivery to liver and manufacturing method thereof
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
JP7757277B2 (ja) 2019-10-14 2025-10-21 アストラゼネカ・アクチエボラーグ Pnpla3発現のモジュレーター
JP7676377B2 (ja) 2019-10-22 2025-05-14 アルナイラム ファーマシューティカルズ, インコーポレイテッド 補体成分C3 iRNA組成物およびその使用方法
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
AR121446A1 (es) 2020-02-28 2022-06-08 Ionis Pharmaceuticals Inc Compuestos y métodos para modular smn2
MX2022011806A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
JP2023520764A (ja) 2020-03-24 2023-05-19 ジェネレーション バイオ カンパニー 第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用
EP4138858A4 (en) 2020-04-21 2024-07-03 Flagship Pioneering, Inc. BIFUNCTIONAL MOLECULES AND METHODS OF USE THEREOF
JP7738573B2 (ja) 2020-05-01 2025-09-12 アイオーニス ファーマシューティカルズ, インコーポレーテッド Atxn1を調節するための化合物及び方法
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN116096899A (zh) 2020-06-29 2023-05-09 Ionis制药公司 调节plp1的化合物和方法
UY39344A (es) 2020-07-28 2022-02-25 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de app
CA3186935A1 (en) 2020-08-07 2022-02-10 Paymaan JAFAR-NEJAD Compounds and methods for modulating scn2a
TW202227101A (zh) 2020-11-18 2022-07-16 美商Ionis製藥公司 用於調節血管收縮素原表現之化合物及方法
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
TW202242111A (zh) 2020-12-18 2022-11-01 美商Ionis製藥公司 用於調節因子xii之化合物及方法
US20240058279A1 (en) 2020-12-21 2024-02-22 Flagship Pioneering Innovations V, Inc. Use of cell turnover factors for increasing tissue regeneration
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物
KR20230137295A (ko) * 2021-01-28 2023-10-04 난징 챔피언 바이오테크놀로지 컴퍼니 리미티드 접합체 및 이의 용도
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
US20230059578A1 (en) 2021-04-06 2023-02-23 Berg Llc Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
EP4320443A1 (en) 2021-04-06 2024-02-14 BPGbio, Inc. Protein markers for the prognosis of breast cancer progression
CA3214819A1 (en) 2021-04-06 2022-10-13 Guisong WANG Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
EP4329884A1 (en) 2021-04-27 2024-03-06 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
MX2023015230A (es) 2021-06-18 2024-01-18 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de ifnar1.
EP4359539A4 (en) 2021-06-23 2025-05-14 University Of Massachusetts ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS OPTIMIZED FOR THE TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CN115920065A (zh) * 2021-08-02 2023-04-07 南方科技大学 一种可靶向去唾液酸糖蛋白受体的配体及其缀合物与用途
MX2024001194A (es) 2021-08-03 2024-02-27 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
CA3233755A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
EP4423273A1 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
WO2023086292A2 (en) 2021-11-10 2023-05-19 University Of Rochester Gata4-targeted therapeutics for treatment of cardiac hypertrophy
EP4430187A2 (en) 2021-11-10 2024-09-18 University of Rochester Antisense oligonucleotides for modifying protein expression
CN116917477B (zh) * 2022-01-30 2024-04-09 大睿生物医药科技(上海)有限公司 含有n-乙酰半乳糖胺的靶向配体
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
WO2023178144A2 (en) 2022-03-16 2023-09-21 Empirico Inc. Galnac compositions for improving sirna bioavailability
AU2023245603A1 (en) 2022-03-28 2024-11-07 Empirico Inc. Modified oligonucleotides
CN117264950A (zh) * 2022-07-07 2023-12-22 北京福元医药股份有限公司 用于抑制c5基因表达的双链核糖核酸及其修饰物、缀合物和用途
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024050261A1 (en) 2022-08-29 2024-03-07 University Of Rochester Antisense oligonucleotide-based anti-fibrotic therapeutics
KR20250075637A (ko) 2022-09-23 2025-05-28 아이오니스 파마수티컬즈, 인코포레이티드 Mecp2 발현을 감소시키기 위한 화합물 및 방법(compounds and methods for reducing mecp2 expression)
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
TW202448484A (zh) 2023-04-20 2024-12-16 美商雅迪克斯製藥公司 Mapt調節組合物及其使用方法
WO2024238396A1 (en) 2023-05-12 2024-11-21 Adarx Pharmaceuticals, Inc. Nmda ligand conjugated compounds and uses thereof
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
TW202506137A (zh) 2023-06-20 2025-02-16 美商雅迪克斯製藥公司 Lrrk2調節組合物及其使用方法
GB202314724D0 (en) 2023-09-26 2023-11-08 Astrazeneca Ab compounds and methods for reducing psd3 expression
WO2025196505A2 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
ES2665274T5 (es) * 2002-08-05 2021-06-30 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
EP1560840B1 (en) * 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2005222902B2 (en) * 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP3705125B1 (en) * 2007-12-04 2023-07-05 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
EP2245039A4 (en) * 2008-01-31 2012-06-06 Alnylam Pharmaceuticals Inc OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
WO2009142822A2 (en) * 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. 2-f modified rna interference agents
AU2009234266B2 (en) * 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2442792A4 (en) 2009-06-15 2015-12-23 Alnylam Pharmaceuticals Inc TESTING GENE PCSK9 LIPID-FORMULATED DSRNA
EP3921593B1 (en) 2019-02-04 2023-03-15 Detnet South Africa (Pty) Ltd Boost pump
KR102318555B1 (ko) 2020-03-19 2021-10-29 한국과학기술연구원 광소자용 역나노콘과 그 제조방법

Similar Documents

Publication Publication Date Title
JP2013541334A5 (enExample)
EP3011028B1 (en) Compositions and methods for modulation of target nucleic acids
EP3524680B1 (en) Compositions and methods for modulating ttr expression
US11116843B2 (en) Conjugated antisense compounds and their use
KR102522059B1 (ko) 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
US20220081689A1 (en) Compounds and Methods for Use in Dystrophin Transcript
JP2017525705A5 (enExample)
JP2019503394A5 (enExample)
US20220073914A1 (en) Compounds and methods for modulation of smn2
EP3724206B1 (en) Conjugated antisense compounds and their use
JP2016518841A (ja) 細胞取り込みの向上のための化合物および方法
CA3037042A1 (en) Modified oligonucleotides and methods of use
EP3271372A2 (en) Antisense-induced exon exclusion in myostatin
JPWO2021188626A5 (enExample)
US11833221B2 (en) Oligomeric compounds for reducing DMPK expression
AU2017297624B2 (en) Compounds and methods for modulation of transcript processing
CN110177877B (zh) 反义寡核苷酸
EP3077510B1 (en) Antisense compounds and uses thereof
Watts The medicinal chemistry of antisense oligonucleotides
EP3851531A1 (en) Antisense-induced exon exclusion in type vii collagen
HK40008058A (en) Compounds and methods for modulation of smn2
HK40008058B (en) Compounds and methods for modulation of smn2
HK40011555B (en) Compositions and methods for modulating ttr expression
HK40011555A (en) Compositions and methods for modulating ttr expression